Thrombosomes® in Bleeding Thrombocytopenic Patients Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-05

Study Completion Date

2022-01-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective, multicenter, randomized, open-label, Phase 2, parallel, dose ranging, multidose trial will enroll patients into 3 Thrombosomes dose groups and 1 control liquid stored platelets (LSP) group in order to evaluate, in a dose-escalation manner, the safety, and impact on bleeding, and the preliminary effect on coagulation measures of increasing doses of allogeneic Thrombosomes in comparison to standard of care, LSP.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Thrombosomes® in Bleeding Thrombocytopenic Patients

NCT03394755

Thrombocytopenia Hematologic Diseases Bone Marrow Aplasia

COMPLETED PHASE1

Strategies for Transfusion of Platelets (SToP)

NCT00420914

Thrombocytopenia

TERMINATED PHASE3

Avatrombopag for the Treatment of Thrombocytopenia After Donor Hematopoietic Stem Cell Transplant

NCT04312789

Platelet Disorder

WITHDRAWN PHASE2

Efficacy of Mirasol-treated Apheresis Platelets in Patients With Hypoproliferative Thrombocytopenia

NCT02964325

Hematologic Malignancies Hypoproliferative Thrombocytopenia

TERMINATED NA

Evaluation of the Safety and Immunogenicity of Autologous Thrombosomes® in Healthy Human Subjects; A Microdose Escalation Study (Cohorts 1 - 4) and Repeat Microdose Immunogenicity Study (Cohort 5)

NCT02223117

Healthy

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thrombocytopenia Hematologic Malignancy Bone Marrow Aplasia Myeloproliferative Disorders Myelodysplastic Syndromes Platelet Refractoriness

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Dose Ranging Multidose

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Human platelet derived lyophilized hemostatic

Intervention Type BIOLOGICAL

Liquid Stored Platelets (LSP)

Leukocyte reduced apheresis platelets or whole blood derived pooled platelet concentrate equivalent (4-6 units)

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adults (≥18 years) with TCP as defined by BOTH (a) and (b):

1. a platlet count of ≤ 70,000 platelets/μL blood
2. ANY ONE OR MORE of (1-3):

1. confirmed diagnosis of hematologic malignancy, myeloproliferative disorder, myelodysplastic syndrome, or aplasia
2. undergoing chemotherapy, immunotherapy, radiation therapy or hematopoietic stem cell transplantation
3. refractory to platelet transfusion defined as two 1-hour CCI of \<5,000 on consecutive transfusions of LSP or as defined by local site policy (Sacher, 2003)
2. WHO Bleeding Score of 2 or 3
3. Able to provide informed consent directly or through legally authorized representative, and comply with treatment and monitoring
4. Negative pregnancy test for women of childbearing potential

Exclusion Criteria

1. Any disorder or condition related to any venous thrombosis, embolism, or ischemia within the past 3 months
2. Any disorder or condition related to arterial thrombosis including: ischemia, stroke, MI, or stent placement, within past 6 months
3. Any valve replacement and/or repair of left atrial appendance occlusion device
4. Sinusoidal obstruction syndrom (veno-occlusive disease) or cytopkine release syndrome associated with CAR-T cell therapy
5. Refusal to accept blood products
6. Liver enzyme blood levels greater than 3× the upper limit of normal (ULN)
7. Blood creatinine level greater than 3× ULN
8. Received platelet inhibitor drugs, cyclooxygenase-2 (COX-2) inhibitors, or nonsteroidal anti-inflammatory drugs within 5 days prior to infusion
9. Currently (at the time of randomization) receiving anticoagulant therapy or antiplatelet therapy. Low dose prophylaxis for line clots is not excluded.
10. Receipt of any pro-coagulant agents (e.g., DDAVP, recombinant Factor VIIa or prothrombin complex concentrates (PCC)) other than Tranexamic Acid (TXA) or Epsilon Aminocaproic Acid (EACA, Amicar), within 48 hours of first infusion, or with known hypercoagulable state
11. WHO Bleeding Score of 2 solely due to lumbar puncture, retinal bleeding or GI bleeding or WHO Bleeding Score of 3 solely due to lumbar puncture
12. Receiving L-asparaginase as part of a current cycle of treatment
13. Known inherited or acquired bleeding disorder including, but not limited to: acquired storage pool deficiency or paraproteinemia with platelet inhibition
14. Known inherited or acquired prothrombotic disorders, including antiphospholipid syndrome (Those with lupus anticoagulant or positive antiphospholipid serology without thrombosis are NOT excluded.)
15. Anuria
16. On dialysis
17. Receipt of an investigational drug within 1 month before first infusion, other than for treatment of their underlying disease
18. Females pregnant or nursing or unwilling to use contraception during and for 30 days after taking the study product (females). Evidence of effective birth control may be used, at the discretion of the physician
19. Acute or chronic medical disorder that, in the opinion of the Investigator, would impair the ability of the patient to receive or respond to study treatment
20. Prior participation in this study with successful infusion of the investigational or control product
21. Currently enrolled in other trials not related to their primary disease process or involving platelet transfusions, platelet growth factors, or other pro-coagulant agents

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No